

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**

### **宜明昂科生物醫藥技術（上海）股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1541)**

## **DISCLOSEABLE TRANSACTION SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCT**

### **SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCT**

The Board announces that on June 17, 2026, the Company agreed to subscribe for a wealth management product (the “**Subscription**”) in the amount of HK\$87,500,000 from Vital Ventures (the “**Vital Subscription Product**”). The Subscription was funded by the Group’s internal surplus cash reserve.

### **IMPLICATIONS UNDER THE LISTING RULES**

As one or more applicable percentage ratios calculated pursuant to Rule 14.07 of the Listing Rules in respect of the Subscription exceed 5% but are lower than 25%, the Subscription constitutes a discloseable transaction of the Company under relevant requirements of Chapter 14 of the Listing Rules, and is subject to the notification and announcement requirements as set out under Rule 14.34 of the Listing Rules but exempt from the Shareholders’ approval requirement under Chapter 14 of the Listing Rules.

## **THE SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCT**

On June 17, 2026, the Company agreed to subscribe for the Vital Subscription Product in the amount of HK\$87,500,000 from Vital Ventures. The major terms and conditions of the Subscription are summarised below:

Expected effective date of the Subscription: June 18, 2026

Name of the product: New Horizon cash management funds

Parties: (i) Vital Ventures, as the issuer;  
(ii) the Company, as the subscriber;

Type of the product: Cash management funds

Principal amount subscribed: HK\$87,500,000

Terms of investment: No fixed term, redeemable upon giving notice five business days in advance by the Company

Expected annualized rate of return: expected to be 1.5%–4.5%, subject to the actual return rate of the underlying assets

Investment scope of the product: Underlying subject of cash management products, e.g., cash, bank deposits, bank certificates, short-term U.S. treasury bonds, or other cash management investment instruments

## **BASIS OF DETERMINATION FOR THE CONSIDERATION**

The Directors confirmed that the consideration for the Subscription was determined on the basis of commercial terms negotiated at arm's length among the Company and Vital Ventures, having considered the surplus cash reserves of the Group available for treasury management purpose.

## **REASONS FOR AND BENEFITS OF THE SUBSCRIPTION**

The Directors are of the view that (i) appropriate wealth management with low risk exposure is conducive to enhancing the utilisation of capital and increasing income from idle funds of the Group; (ii) diversified, readily redeemable investments in cash management products are conducive to enhancing the safety and flexibility of cash management; and (iii) the Subscription was funded by the Group's internal surplus cash reserves, and thus would not affect the Group's working capital position or operation. Accordingly, the Directors consider that the terms of the Subscription are fair and reasonable, on normal commercial terms, and in the interests of the Company and the Shareholders as a whole.

## **INFORMATION ON THE PARTIES**

### **The Company**

The Company is a joint stock company incorporated in the PRC with limited liability on June 14, 2022. The Company is a clinical-stage biotechnology company dedicated to the development of immuno-oncology therapies.

### **Vital Ventures**

Vital Ventures is a segregated portfolio established under Vital Ventures SPC under the laws of the Cayman Islands on May 22, 2023. Vital Ventures SPC is an exempted company with limited liability registered as a segregated portfolio company under the laws of the Cayman Islands on May 22, 2023, which is ultimately controlled by Bingjun Liu. Vital Ventures is principally engaged in the management and investment of low-risk assets denominated in US dollars.

As of the date of this announcement and to the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, each of Vital Ventures and its ultimate beneficial owner is a third party independent of each of the Company and its connected persons (as defined under the Listing Rules).

## **IMPLICATIONS UNDER THE LISTING RULES**

As one or more applicable percentage ratios calculated pursuant to Rule 14.07 of the Listing Rules in respect of the Subscription exceed 5% but are lower than 25%, the Subscription constitutes a discloseable transaction of the Company under relevant requirements of Chapter 14 of the Listing Rules, and is subject to the notification and announcement requirements as set out under Rule 14.34 of the Listing Rules but exempt from the Shareholders' approval requirement under Chapter 14 of the Listing Rules.

## DEFINITIONS

In this announcement, unless the context otherwise requires, the following terms shall have the following meanings:

“Board”	the board of Directors
“Company”	ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (宜明昂科生物醫藥技術(上海)股份有限公司), a joint stock company incorporated in the People’s Republic of China with limited liability on June 14, 2022, the H shares of which are listed on the Stock Exchange (stock code: 1541), or, where the context requires (as the case may be), its predecessor, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (宜明昂科生物醫藥技術(上海)有限公司), a limited liability company established in the PRC on June 18, 2015
“Director(s)”	the director(s) of the Company
“Group”	the Company and its subsidiaries
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (as amended from time to time)
“percentage ratios”	have the same meaning as ascribed to them under the Listing Rules
“PRC”	the People’s Republic of China, and except where the context otherwise requires, references in this announcement to the PRC or Mainland China exclude Hong Kong, China, Macau, China and Taiwan, China
“Shareholder(s)”	holder(s) of the shares of the Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited

“Vital Ventures”

Vital Ventures SPC (on behalf of Horizon Fund SP), an exempted company with limited liability registered as a segregated portfolio company under the laws of the Cayman Islands on May 22, 2023

“%”

per cent.

By order of the Board  
**ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**  
**宜明昂科生物醫藥技術（上海）股份有限公司**  
**Tian Wenzhi**  
*Chairman and Executive Director*

Shanghai, the PRC, June 17, 2026

*As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi, Mr. Li Song, Ms. Guan Mei and Mr. Zhang Ruliang as executive Directors; (ii) Dr. Xu Cong and Ms. Fu Dawei as non-executive Directors; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.*